Parkinson’s disease (PD) is characterized by mitochondrial dysfunction and the accumulation of α-synuclein (αsyn), and lowering αsyn levels is a leading therapeutic strategy for PD that is already under clinical investigation. Here, SNCA is linked to Parkinson disease.